The stock will trade on upcoming clinical catalysts: Phase 3 Study 304 topline data in 2H26 and Study 306 topline data in 1H27. Monitor for any data readouts or regulatory updates that could derail the VDPHL01 approval timeline.
Price Chart
Executive Summary
Veradermics reported Q2 2026 net loss of $23.5M, widening from a $15.6M loss in Q2 2025, with no revenue and increasing R&D and G&A expenses as it advances its lead candidate VDPHL01. The company highlighted positive Phase 2 results in female pattern hair loss and completion of enrollment in the registration-directed Study 306, with multiple data milestones expected in 2H26 and 1H27. Cash position strengthened to $819.9M, expected to fund operations into 2030, but the lack of revenue and growing losses keep the stock's near-term trajectory tied to clinical catalysts rather than financial performance.
Key Financial Metrics
Key Facts
- Net loss of $23.5M for Q2 2026, compared to $15.6M in Q2 2025.
- Cash, cash equivalents, and marketable securities totaled $819.9M as of June 30, 2026.
- Positive topline results from Phase 2 Study 207 in female pattern hair loss announced in July 2026.
- Enrollment completed for Phase 2/3 Study 306 in female pattern hair loss (556 participants); topline data expected in 1H27.
- Topline data from confirmatory Phase 3 Study 304 in male pattern hair loss and 12-month data from Study 302 both anticipated in 2H26.
- R&D expenses were $18.6M in Q2 2026, up from $14.3M in Q2 2025.
- G&A expenses were $10.9M in Q2 2026, up from $1.7M in Q2 2025.
- Company raised approximately $472.0M in aggregate gross proceeds in May 2026 through a follow-on offering and concurrent private placement.
Financial Impact
Net loss widened by $7.9M year-over-year to $23.5M; cash position increased by $678M from year-end 2025 to $819.9M.
Risk Factors
- Clinical trial failure or delay for VDPHL01
- Regulatory hurdles or safety concerns
- Cash burn rate may require future financing
- Competition from existing and pipeline hair loss treatments
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001827635-26-000028 |
| Document: mane-20260811.htm | 0001827635-26-000028 |
| Document: 0001827635-26-000028-index-headers.html | 0001827635-26-000028 |
| Document: 0001827635-26-000028-index.html | 0001827635-26-000028 |
| Document: 0001827635-26-000028.txt | 0001827635-26-000028 |
| 8-K Data (Synthetic) | 0001827635-26-000028 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | 8-K | $122.28 | awaiting T+5 | — | $139.46 (+14.05%) |
Oct 13, 2026 12d ago | SC 13G | $116.26 $127.11 | ▲ +9.33% | ▲ +10.48% | $139.46 (+19.96%) |
Aug 21, 2026 9w ago | Insider Cluster | $98.46 $98.41 | ▲ +0.05% | ▲ +0.52% | $139.46 (−41.64%) |
Aug 20, 2026 9w ago | 3 | $102.82 $97.93 | ▼ −4.76% | ▼ −5.23% | $139.46 (+35.64%) |
Aug 18, 2026 9w ago | Insider Cluster | $111.23 $102.80 | ▼ −7.58% | ▼ −7.19% | $139.46 (+25.38%) |
Aug 11, 2026 10w ago | 8-K | $110.75 $111.31 | ▲ +0.51% | ▲ +0.91% | $139.46 (+25.92%) |
Aug 7, 2026 11w ago | S-1 | $110.75 $108.22 | ▲ +2.28% | ▲ +2.24% | $139.46 (−25.92%) |
Aug 7, 2026 11w ago | Institutional Cluster | $114.39 $112.71 | ▼ −1.47% | ▼ −1.87% | $139.46 (+21.92%) |
Jul 15, 2026 14w ago | 8-K | $123.70 $109.85 | ▼ −11.20% | ▼ −10.22% | $139.46 (+12.74%) |
May 12, 2026 23w ago | 8-K | $103.90 $100.38 | ▼ −3.39% | ▼ −3.47% | $139.46 (+34.23%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers